Connect
MJA
MJA

Point-of-care testing for coeliac disease antibodies — what is the evidence?

Evan D Newnham and Jason A Tye-Din, Evan D Newnham Jason A Tye-Din on behalf of the Coeliac Australia Medical Advisory Committee
Med J Aust 2015; 202 (8): 418-419. || doi: 10.5694/mja14.01397
Published online: 4 May 2015

To the Editor: The recent introduction of rapid point-of-care testing (PoCT) in Australian pharmacies to screen for coeliac disease has attracted controversy1 and provides an important opportunity to review the current literature.

  • Evan D Newnham1
  • Jason A Tye-Din2
  • Evan D Newnham Jason A Tye-Din on behalf of the Coeliac Australia Medical Advisory Committee

  • 0 behalf of the Coeliac Australia Medical Advisory Committee
  • 1 Eastern Health Clinical School, Melbourne, VIC.
  • 2 Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC.

Correspondence: evan.newnham@monash.edu

Competing interests:

Jason Tye-Din holds patents pertaining to the use of gluten peptides in therapeutics, diagnostics and non-toxic gluten for coeliac disease. He is a consultant to ImmusanT and a shareholder of Nexpep.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.